Using Qube 384, we profiled a panel of NaV inhibitors across species, providing valuable translational insight early in analgesic drug discovery.
Highly-validated screening assays developed by Metrion are capable of confidently identifying modulators of the lysosomal TRPML1 channel. The TRPML1 variant that lacks the endo-lysosomal retention sequences (TRPML1-4A) is used, enabling the channel to express at the plasma membrane. As such, channel behaviour can be successfully characterised by:
Read our case study: Development of TRPML1-4A assays across manual, automated patch-clamp, and fluorescence-based platforms
Contact Metrion to advance your preclinical drug discovery project
Using Qube 384, we profiled a panel of NaV inhibitors across species, providing valuable translational insight early in analgesic drug discovery.
We explore hNav1.9's unique fast and slow inactivation properties using Qube 384 and QPatch 48 platforms, helping to build more predictive screening assays for state-dependent inhibitors.